Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece

NCT01558089 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01558089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01558089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 31, 2013
Completion date
May 31, 2015
Enrollment
76 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis